Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BLOOD 2020-02, Vol.135 (7), p.491-504
Hauptverfasser:	Brandão, Leonardo R., Albisetti, Manuela, Halton, Jacqueline, Bomgaars, Lisa, Chalmers, Elizabeth, Mitchell, Lesley G., Nurmeev, Ildar, Svirin, Pavel, Kuhn, Tomas, Zapletal, Ondrej, Tartakovsky, Igor, Simetzberger, Monika, Huang, Fenglei, Sun, Zhichao, Kreuzer, Jörg, Gropper, Savion, Brueckmann, Martina, Luciani, Matteo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Child Child, Preschool Clinical Trials and Observations Dabigatran - adverse effects Dabigatran - pharmacokinetics Dabigatran - therapeutic use Endpoint Determination Female Follow-Up Studies Hematology Humans Infant Kaplan-Meier Estimate Life Sciences & Biomedicine Male Medicin och hälsovetenskap Risk Factors Science & Technology Secondary Prevention Time Factors Venous Thromboembolism - drug therapy Venous Thromboembolism - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to
ISSN:	0006-4971 1528-0020 1528-0020
DOI:	10.1182/blood.2019000998